Tenosynovial giant cell tumor, diffuse type
Also known as TGCT, TSGCT, Tenosynovial Giant Cell Tumor, diffuse giant cell neoplasm of Tenosynovium+26 more
TGCT, TSGCT, Tenosynovial Giant Cell Tumor, diffuse giant cell neoplasm of Tenosynovium, diffuse giant cell neoplasm of tendon sheath, diffuse giant cell neoplasm of the Tenosynovium, diffuse giant cell tumor of Tenosynovium, diffuse giant cell tumor of tendon sheath, diffuse giant cell tumor of the Tenosynovium, diffuse giant cell tumour of Tenosynovium, diffuse giant cell tumour of tendon sheath, diffuse giant cell tumour of the Tenosynovium, diffuse tenosynovial giant cell neoplasm, diffuse tenosynovial giant cell tumor, diffuse tenosynovial giant cell tumour, pigmented villonodular synovitis, villous tenosynovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor diffuse type, tenosynovial giant cell tumors, tenosynovial giant cell tumour, tenosynovial giant cell tumour diffuse type, tenosynovial giant cell tumours, villonodular synovitis, diffuse pigmented villonodular synovitis, diffuse-type GCT, diffuse-type giant cell tumor, diffuse-type giant cell tumour, localised pigmented villonodular synovitis, localized pigmented villonodular synovitis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 regulatory approval from EMA on record.
Regulatory UpdatesViewHide
- 2025-09-17Approval — Vimseltinib DihydrateRomvimza is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.
- 2025-09-17RegulatoryApproval — Vimseltinib DihydrateRomvimza is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Romvimza is indicated for treatment of adult patients with symptomatic tenosynovial giant… (2025)
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
TGCT, TSGCT, Tenosynovial Giant Cell Tumor, diffuse giant cell neoplasm of Tenosynovium, diffuse giant cell neoplasm of tendon sheath, diffuse giant cell neoplasm of the Tenosynovium, diffuse giant cell tumor of Tenosynovium, diffuse giant cell tumor of tendon sheath, diffuse giant cell tumor of the Tenosynovium, diffuse giant cell tumour of Tenosynovium, diffuse giant cell tumour of tendon sheath, diffuse giant cell tumour of the Tenosynovium, diffuse tenosynovial giant cell neoplasm, diffuse tenosynovial giant cell tumor, diffuse tenosynovial giant cell tumour, pigmented villonodular synovitis, villous tenosynovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor diffuse type, tenosynovial giant cell tumors, tenosynovial giant cell tumour, tenosynovial giant cell tumour diffuse type, tenosynovial giant cell tumours, villonodular synovitis, diffuse pigmented villonodular synovitis, diffuse-type GCT, diffuse-type giant cell tumor, diffuse-type giant cell tumour, localised pigmented villonodular synovitis, localized pigmented villonodular synovitis
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Related entities are derived from literature co-mention (studied together) — associative, not causal.